Javascript is disabled in your browser

Startbase requires Javascript in order to display content.
Please check your browser settings and enable Javascript-Support for this website.

Biotech

News Lilly is acquiring AtaiBeckley for up to $3.8 billion and is focusing on new treatments for treatment-resistant depression Lilly is acquiring AtaiBeckley and significantly expanding its neuroscience pipeline. The focus is on a novel therapy for treatment-resistant depression.

Marc Nemitz 20.07.2026

News 5 million euros for Graph Therapeutics Using AI, patient cells, and multi-omics data, Graph Therapeutics aims to unravel the causes of complex immune disorders.

Marc Nemitz 02.07.2026

News Epitome Therapeutics Launches with 4 Million Euros The EMBL spin-off is developing CADENCE, a platform for the precise control of gene expression, and is launching with €4 million in funding.

Marc Nemitz 30.06.2026

News Isomorphic Labs raises 2.1 billion US dollars in Series B funding 2.1 billion dollars for AI drug development. Isomorphic Labs is scaling its AI drug design platform and wants to fundamentally accelerate drug research.

Marc Nemitz 13.05.2026

News Cellply raises 7.15 million euros Cellply secures 7.15 million euros for the expansion of its AI-based cell analysis platform VivaCyte.

Marc Nemitz 11.05.2026

News Primogene raises 4.1 million euros for industrial breast milk molecules Biotech from Leipzig makes ingredients from breast milk scalable for the first time. Enzyme tech could change markets from infant formula to pharmaceuticals.

Marc Nemitz 29.04.2026

News BioThrust secures pre-seed extension for cell and gene therapy technology New funding to accelerate pilot studies and scaling. Bioreactor platform could significantly reduce costs for therapies.

Marc Nemitz 28.04.2026

News Cellbricks Therapeutics raises 10 million euros for bio-printed tissues Cellbricks drives living implants towards the clinic. From tissue engineering to organs, the biotech start-up is scaling up.

Marc Nemitz 25.03.2026

News NRW.BANK invests in iDEL Therapeutics iDEL Therapeutics raises 9 million euros for new approaches in cancer therapy. The technology is designed to transport active substances specifically into cancer cells and reduce side effects.

Marc Nemitz 18.03.2026

News BioNTech founders leave the company BioNTech founders Uğur Şahin and Özlem Türeci are planning a new mRNA company. BioNTech is already looking for new management. Worried looks in Mainz and Marburg.

Marc Nemitz 10.03.2026

1
2
3
4
5